AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) trades at $10.05 with AI Score 45/100 (Grade C). AgomAb Therapeutics N. V. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic fibrotic diseases. Market cap: $495.12M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for AGMB: AGMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AGMB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AGMB: the 1 perspectives are evenly split.
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Healthcare & Pipeline Overview
AgomAb Therapeutics N.V. specializes in developing novel disease-modifying therapies for chronic fibrotic diseases, with a focus on innovative treatments that address significant unmet medical needs in immunology and inflammatory diseases.
What Is the Investment Thesis for AGMB?
AgomAb Therapeutics N.V. presents a compelling investment thesis driven by its robust pipeline of innovative therapies targeting chronic fibrotic diseases, which are currently underserved in the market. The company's lead candidate, Ontunisertib, is in Phase 2a trials, with the potential to capture significant market share in the Fibrostenosing Crohn's disease market, valued at approximately $5 billion. Additionally, AGMB-447's development for idiopathic pulmonary fibrosis, a condition with a market size exceeding $3 billion, further enhances growth prospects. The company's strategic focus on unmet medical needs positions it favorably against competitors, potentially leading to lucrative partnerships or acquisitions as clinical trials progress. However, investors should remain cautious of the inherent risks associated with clinical-stage biopharmaceuticals, including trial outcomes and regulatory approval timelines.
Based on FMP financials and quantitative analysis
AGMB Key Highlights
- Market Cap: $0.00B, indicating early-stage development.
- P/E Ratio: -9.49, reflecting current operational losses typical of clinical-stage companies.
- No dividend yield, aligning with reinvestment strategy in R&D.
- 57 employees dedicated to advancing innovative therapies.
- Focus on chronic fibrotic diseases, a high unmet need market.
Who Are AGMB's Competitors?
AGMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INCY Incyte Corporation | $108.53 | +0.65% | 22B | 64 |
| AMGN Amgen Inc. | $354.13 | +0.02% | $191.13B | 59 |
| GILD Gilead Sciences, Inc. | $125.59 | -0.22% | 156B | 55 |
| VRTX Vertex Pharmaceuticals Incorporated | $444.96 | -0.02% | $112.93B | 58 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | $2.42B | 79 |
| ABVX Abivax S.A. | $96.55 | -4.28% | 7B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AGMB's Key Strengths?
- Innovative pipeline targeting chronic fibrotic diseases.
- Strong focus on unmet medical needs.
- Experienced leadership with a background in biopharmaceuticals.
- Potential for significant market capture in niche therapeutic areas.
What Are AGMB's Weaknesses?
- Clinical-stage company with no approved products yet.
- Dependence on successful trial outcomes for future growth.
- Limited financial resources typical of early-stage biopharmaceuticals.
- Market perception risks associated with clinical trial failures.
What Could Drive AGMB Stock Higher?
- Results from Phase 2a trials for Ontunisertib expected in Q3 2026.
- Phase 1 trials for AGMB-447 are currently underway.
- Potential partnerships with larger biopharmaceutical companies to enhance R&D capabilities.
- Continued development of AGMB-101 in preclinical studies.
- Regulatory submissions for trial expansions anticipated in late 2026.
What Are the Key Risks for AGMB?
- Clinical trial failures could hinder product development timelines.
- Regulatory approval processes may delay market entry.
- Competitive pressures from established biopharmaceutical companies.
- Market fluctuations could impact funding and operational capacity.
What Are the Growth Opportunities for AGMB?
- Growth opportunity 1: Ontunisertib (AGMB-129) is currently in Phase 2a trials for Fibrostenosing Crohn's disease, a market projected to reach $5 billion by 2027. Successful trial outcomes could lead to expedited regulatory approval and significant market capture, positioning AgomAb as a leader in this therapeutic area.
- Growth opportunity 2: AGMB-447, an inhaled small molecule inhibitor for idiopathic pulmonary fibrosis, is in Phase 1 trials. The idiopathic pulmonary fibrosis market is expected to exceed $3 billion by 2026, and positive clinical results could facilitate partnerships with larger pharmaceutical companies, accelerating commercialization efforts.
- Growth opportunity 3: The development of AGMB-101, a HGF-mimetic monoclonal antibody, targets a novel mechanism of action in fibrosis. As the market for monoclonal antibodies continues to grow, with a projected CAGR of 10% through 2025, AgomAb's unique approach may capture interest from investors and collaborators.
- Growth opportunity 4: Expansion into additional chronic inflammatory disease indications could diversify AgomAb's pipeline. The global market for inflammatory diseases is projected to grow significantly, providing opportunities for new product development and strategic collaborations.
- Growth opportunity 5: Strategic partnerships with larger biopharmaceutical companies could enhance AgomAb's research capabilities and funding. Collaborations could lead to shared resources and expertise, accelerating the development and commercialization of AgomAb's innovative therapies.
What Opportunities Does AGMB Have?
- Growing market for chronic fibrotic diseases.
- Potential partnerships with larger pharmaceutical companies.
- Expansion into additional therapeutic areas.
- Increased investment in biotechnology and healthcare innovation.
What Threats Does AGMB Face?
- Intense competition from established biopharmaceutical companies.
- Regulatory hurdles and approval risks for new therapies.
- Market volatility impacting funding and investment.
- Potential for clinical trial failures affecting company viability.
What Are AGMB's Competitive Advantages?
- Focus on chronic fibrotic diseases with high unmet medical needs.
- Innovative drug candidates targeting specific pathways in fibrosis.
- Strong preclinical and clinical development pipeline.
- Experienced leadership team with expertise in biopharmaceuticals.
- Potential for strategic partnerships to enhance market position.
What Does AGMB Do?
AgomAb Therapeutics N.V., incorporated in 2017 and headquartered in Antwerp, Belgium, is a clinical-stage biopharmaceutical company dedicated to developing innovative disease-modifying therapies for immunology and inflammatory diseases. The company focuses particularly on chronic fibrotic indications that present significant unmet medical needs. AgomAb's product pipeline features Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, currently in Phase 2a clinical trials aimed at treating Fibrostenosing Crohn's disease. Additionally, AGMB-447, an inhaled small molecule inhibitor, is in Phase 1 clinical trials for idiopathic pulmonary fibrosis. The company also develops AGMB-101, a HGF-mimetic monoclonal antibody that stimulates the MET receptor, showing promising antifibrotic and regenerative activity in preclinical models. With a dedicated team of 57 employees, AgomAb is committed to advancing its innovative therapies through rigorous clinical development, aiming to provide effective solutions for patients suffering from chronic fibrotic diseases.
What Products and Services Does AGMB Offer?
- Develop innovative therapies for chronic fibrotic diseases.
- Focus on immunology and inflammatory disease indications.
- Conduct clinical trials to test the efficacy and safety of drug candidates.
- Target unmet medical needs in the biopharmaceutical market.
- Utilize small molecule inhibitors and monoclonal antibodies in drug development.
- Work towards regulatory approvals for novel therapies.
How Does AGMB Make Money?
- Generate revenue through the commercialization of approved therapies.
- Engage in strategic partnerships and collaborations for funding and development.
- Focus on R&D investments to advance clinical trials and product pipeline.
- Leverage intellectual property for potential licensing agreements.
- Aim for acquisition opportunities by larger pharmaceutical companies.
What Industry Does AGMB Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug discovery and a rising demand for innovative therapies. The global market for fibrotic diseases is expanding, with an increasing prevalence of conditions such as idiopathic pulmonary fibrosis and Crohn's disease. AgomAb Therapeutics N.V. is strategically positioned within this landscape, focusing on chronic fibrotic diseases that lack effective treatments. The competitive landscape includes several biopharmaceutical companies, but AgomAb's unique approach to targeting specific pathways in fibrosis differentiates it from others in the field.
Who Are AGMB's Key Customers?
- Patients suffering from chronic fibrotic diseases.
- Healthcare providers seeking innovative treatment options.
- Pharmaceutical partners interested in collaboration and licensing.
- Investors looking for opportunities in the biopharmaceutical sector.
- Regulatory bodies for drug approval and market entry.
AGMB Financials
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AGMB Latest News
-
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
globenewswire.com · Apr 23, 2026
AGMB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AGMB.
Price Targets
Wall Street price target analysis for AGMB.
AGMB MoonshotScore
What does this score mean?
The MoonshotScore rates AGMB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tim Knotnerus
CEO
Tim Knotnerus has extensive experience in the biopharmaceutical industry, having held various leadership roles in drug development and commercialization. He holds a degree in Biotechnology and has a strong track record in managing clinical trials and product launches.
Track Record: Under Tim's leadership, AgomAb has successfully advanced its pipeline candidates through critical clinical phases, positioning the company for future growth and potential partnerships.
What Investors Ask About AgomAb Therapeutics N.V. American Depositary Shares (AGMB) — Healthcare
What does AgomAb Therapeutics N.V. American Depositary Shares do?
AgomAb Therapeutics N.V. develops novel disease-modifying therapies specifically targeting chronic fibrotic diseases. The company's pipeline includes innovative drug candidates like Ontunisertib for Fibrostenosing Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis, aiming to address significant unmet medical needs in the healthcare sector.
What do analysts say about AGMB stock?
Analysts are closely monitoring AgomAb Therapeutics N.V. for its innovative approach to treating chronic fibrotic diseases. With a focus on clinical trial outcomes and the potential for strategic partnerships, AGMB's valuation metrics reflect the high-risk, high-reward nature of clinical-stage biopharmaceuticals.
What are the main risks for AGMB?
AgomAb Therapeutics N.V. faces several risks, including the potential for clinical trial failures that could impact product development timelines. Regulatory approval processes are ongoing and may introduce delays, while competitive pressures from established biopharmaceutical companies could affect market positioning and funding opportunities.
What are the key factors to evaluate for AGMB?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) holds an AI score of 45/100 (low). Not financial advice.
How frequently does AGMB data refresh on this page?
AGMB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AGMB's recent stock price performance?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting chronic fibrotic diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AGMB overvalued or undervalued right now?
Valuing AgomAb Therapeutics N.V. American Depositary Shares (AGMB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AGMB?
Before investing in AgomAb Therapeutics N.V. American Depositary Shares (AGMB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company profile and financial metrics. Future projections are based on current pipeline status and industry trends.